Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347214 · ClinicalTrials.gov registry record
dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 6,260
- Enrollment target
NCT03347214: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT03347214 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 6,260 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03347214 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 6,260 participants
- Enrollment target
Study Summary
Background: Researchers do not know much about the causes of congenital heart disease (CHD). They do know that many factors play a role. Some factors are environmental. Some are genetic. But few specific factors have been identified. And researchers do not know how many involve genes. They want to study data that has already been collected from people with CHD and their families. Objectives: To identify genetic variations related to CHD. To study molecules related to vascular disease in order to learn new ways to treat it. Eligibility: People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study Design: Researchers will study data that was already collected in the PCGC. There will be no active participants. Researchers will get access to the data through the coordinating center. They will not download data to local storage devices. The data will have no personally identifying information....
Primary Outcome
de novo variants, SNPs, and CNVs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,260 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2020-01-10 |
What the finished NCT03347214 record still lists
NCT03347214 is an observational study that tracks outcomes without assigning an intervention. Its 6,260 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03347214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03347214 about?
NCT03347214 is a clinical study titled "dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)". Background: Researchers do not know much about the causes of congenital heart disease (CHD). They do know that many factors play a role. Some factors are environmental. Some are genetic. But few specific factors have been identified. And researchers do not know how many involve genes. They want to ...
What is the current status of trial NCT03347214?
This trial is currently completed. The enrollment target is 6,260 participants. The study started on 2017-10-20. Estimated completion is 2020-01-10.
Who is sponsoring clinical trial NCT03347214?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04884802 · 6,254 participants · NA
The GUARDIAN Trial
- NCT03960099 · 6,250 participants · NA
Pictographs for Preventing Wrong-Patient Errors in NICUs
- NCT05440851 · 6,250 participants · NA
Platform of Randomized Adaptive Clinical Trials in Critical Illness
- NCT06566170 · 6,250 participants
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI